Leopoldo Luistro

Author PubWeight™ 3.67^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.	Mol Cancer Ther	2006	1.02
2	High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.	Mol Oncol	2011	1.02
3	RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.	Clin Cancer Res	2013	0.84
4	Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays.	Methods	2012	0.79